A day after Pharmacyte Biotech Inc (OTCMKTS:PMCB) announced the completion of its International Consortium, Goldman Small Cap Research showed up with another sponsored research report for the company. This is Goldman’s second research report on the company within a span of few days. It is to be noted that Goldman Small Cap Research specializes in analyzing micro companies.
The new report
In its report, analyst Rob Goldman discussed how the company gathered a team of elite members and thus, set the stage to progress towards conducting human clinical trials for diabetes and cancer. Goldman gave a detailed account on how Pharmacyte Biotech Inc (OTCMKTS:PMCB)’s CEO Kenneth L. Waggoner has been able to upgrade the quality of his team. He briefed that invaluable human capital has been sourced for the clinical research and execution.
Pointing to the Pharmacyte Biotech Inc (OTCMKTS:PMCB)’s recently formed 16-member International Consortium, Goldman noted that the team includes members who have expertise on both diabetes and cancer treatments. He made a note that each of the members of the Consortium holds an extensive experience in diabetes research, whereas work of many of them has featured in some of the renowned scientific journals.
Goldman did not miss to mention that one of the members, Prof. Ann M Simpson, has already established the fact that Melligen cells encapsulated using the company’s technology are effective enough to reverse Type 1 Diabetes. If the company’s technology, ‘Cell-In-A-Box’ attains similar result in human trials then it has the potential to replace insulin-based diabetes treatment, which accounts $176 billion of the market in the U.S.
Pharmacyte Biotech Inc (OTCMKTS:PMCB)’s Waggoner has previously informed that their International Consortium is complete following the addition of Dr. Thomas Stratmann and Dr. Axel Kornerup Hansen. The news led the stock price of the company during the last trading session, where it surged by nearly 5% to $0.173 as 4.84 million shares traded hands.